Provided by Tiger Trade Technology Pte. Ltd.

Halozyme Therapeutics

108.17
+2.051.93%
Post-market: 108.170.00000.00%19:42 EDT
Volume:1.15M
Turnover:124.20M
Market Cap:12.28B
PE:31.98
High:108.49
Open:106.20
Low:105.91
Close:106.12
52wk High:108.49
52wk Low:61.23
Shares:113.50M
Float Shares:112.00M
Volume Ratio:0.58
T/O Rate:1.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.38
EPS(LYR):2.56
ROE:173.67%
ROA:25.49%
PB:85.53
PE(LYR):42.25

Loading ...

Stock Track | Halozyme Therapeutics Soars 5.24% After-Hours on Q2 Earnings Beat and Raised 2026 Guidance

Stock Track
·
Aug 07

GUIDANCE: (HALO) Halozyme Therapeutics Now Expects 2026 Adjusted EPS Range $8.65-$9.00, vs. FactSet Est of $7.94

MT Newswires Live
·
Aug 07

Halozyme Q2 Revenue Jumps 48%, Raises 2026 Outlook

Reuters
·
Aug 07

Halozyme Therapeutics Q2 Adj. EPS $2.28 Beats $1.84 Estimate, Sales $480.999M Beat $407.493M Estimate

Benzinga Earnings
·
Aug 07

Halozyme Q2 FY26 GAAP Net Income Rises 39% to USD 229.9 Million; Revenue Increases 48% to USD 481 Million

Reuters
·
Aug 07

Halozyme Therapeutics Q2 Adjusted EPS USD 2.28 Vs. IBES Estimate USD 1.84

Reuters
·
Aug 07

Halozyme Therapeutics Outlook FY Adjusted EPS USD 8.65-9

THOMSON REUTERS
·
Aug 07

Earning Preview: Halozyme Therapeutics Q2 revenue is expected to increase by 42.52%, and institutional views are bullish

Earnings Agent
·
Jul 31

4% Undervalued? Halozyme Therapeutics (HALO) Nears Earnings At A Record High

Simply Wall St.
·
Jul 31

Halozyme to Report Q2 Results After Market Close, Host Conference Call

Reuters
·
Jul 23

Halozyme Therapeutics Price Target Maintained with a $95.00/share by HC Wainwright & Co.

Dow Jones
·
Jul 21

Halozyme Therapeutics (HALO) Lands Incyte Deal On A Valuation That Still Looks Undervalued

Simply Wall St.
·
Jul 21

Positive Earnings Outlook and Low Prices Signal Buying Opportunity for Non-Ferrous Metals ETF, Highlighting HALO Trading, Computing Metals, and Strategic Metals

Deep News
·
Jul 21

Halozyme Therapeutics, Incyte Sign Deal to Develop Subcutaneous Formulations of Blood Cancer Drug

MT Newswires Live
·
Jul 20

Halozyme announces global collaboration, license agreement with Incyte

TIPRANKS
·
Jul 20

Halozyme Partners with Incyte on Enhanze Subcutaneous Formulation for Inca033989 Antibody

Reuters
·
Jul 20

Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of Inca033989 Using Its Enhanze® Technology

THOMSON REUTERS
·
Jul 20

Halozyme Therapeutics - Eligible to Receive Royalties on Net Sales of Enhanze Medicines

THOMSON REUTERS
·
Jul 20

Halozyme Therapeutics - to Receive Upfront Payment and Eligible for Milestone Payments from Incyte

THOMSON REUTERS
·
Jul 20

Halozyme Therapeutics - Incyte Granted Rights to Develop Enhanze with Mutcalr Program and Option for Two Additional Targets

THOMSON REUTERS
·
Jul 20